Sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities

Research output: Contribution to journalArticle

6 Citations (Scopus)

Abstract

Since nivolumab significantly prolongs survival in patients with metastatic melanoma, the number of patients administered nivolumab is increasing, but only 30-40% of patients who received nivolumab monotherapy experienced objective tumor regression. Therefore, enhancing its anti-tumor immune response is of great interest to dermato-oncologists. In this report, we present a case of multiple metastatic melanomas in the lung successfully treated with nivolumab (2 mg/kg every 3 weeks for 12 weeks) followed by ipilimumab (3 mg/kg every 3 weeks for 9 weeks), but with severe liver dysfunction.

Original languageEnglish
Pages (from-to)644-649
Number of pages6
JournalCase Reports in Oncology
Volume9
Issue number3
DOIs
Publication statusPublished - 2016 Sep 13

Keywords

  • Immune checkpoint inhibitors
  • Immune-related adverse event
  • Ipilimumab
  • Metastatic melanoma
  • Nivolumab

ASJC Scopus subject areas

  • Oncology

Fingerprint Dive into the research topics of 'Sequential therapy with nivolumab followed by ipilimumab induces complete response in metastatic melanoma of the lung but with severe hepatotoxicities'. Together they form a unique fingerprint.

  • Cite this